Amanda Edmond, PA-C

First-line amivantamab+lazertinib may rewire EGFR-mutant NSCLC, curb resistance, and boost survival — plus proactive clinic management tips.

How chemo-free lung cancer combos like amivantamab+lazertinib boost survival, with tips to manage rashes and stay on therapy.

Prophylactic anticoagulation cuts VTE in lung cancer and helps patients stay on EGFR-targeted combos longer.

Proactive prophylaxis with amivantamab and lazertinib cuts rash, paronychia, and clots using daily skincare, antibiotics, and anticoagulation to keep patients on therapy.

Early COPERNICUS results show subcutaneous amivantamab and proactive VTE and skin prophylaxis sharply reduce reactions, helping NSCLC patients stay on therapy.